Market News AIOpen the app

CTMX stock news · CytomX Therapeutics

Stories about CytomX Therapeutics (CTMX) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for CTMX

Follow CytomX Therapeutics (CTMX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for CTMX
Free on the App Store and Google Play, or on the web.
  1. Nov 12, 2026, 5:40 PM ET · Opinion

    JP Morgan says CytomX Therapeutics is still a good investment.

    Neutral

    JP Morgan kept its favorable rating on CytomX and reported no new financial target or company change. This leaves the company's outlook unchanged.